Bioclinica Introduces Expanded ‘SMART’ Technology Suite

Combines clinical trial technologies for all essential activities in a common data set

By: Kristin Brooks

Managing Editor, Contract Pharma

Bioclinica introduced its expanded and enhanced SMART technology suite available with Medical Imaging, Electronic Data Capture (EDC) and Interactive Response Technology (IRT) combined. It combines Bioclinica clinical trial technologies for all essential activities in a common data set. Investigative sites can now access Medical Imaging, EDC and IRT data via a single portal where they can view, analyze and act on the data. Implementation is underway by a major pharmaceutical company and a leading CRO who are using Bioclinica’s enhanced SMART technology for their global trial portfolio.

“Our clients are already using our best-in-class SMART technology suite to Submit, Manage, Analyze, Report and Transfer medical image data compliant with global data privacy and regulatory requirements. With these new enhancements, we’re providing sponsors and CROs a catalyst to effectively and efficiently consume data throughout the trial,” said Bioclinica president and chief executive officer, David Herron. “By allowing sites to see these critical activities together, SMART eliminates cumbersome reconciliation steps and rework, creating tangible value in efficiency, quality and compliance along the data chain of custody.”

According to the company, additional benefits of the enhanced SMART technology suite include: real-time data reconciliation, automation, reduced data management effort and faster database lock, and using SMART with Bioclinica’s rapid-start IRT gives clients a prototype patient screening, enrollment and dispensing system within days of protocol receipt.

SMART was developed through collaboration among Bioclinica technology developers and in-house medical experts with input from life sciences companies. “The result is clinical trial technology with the flexibility to adapt to clients’ needs regardless of the size or complexity of the study protocol,” Mr. Herron said. “Our end goal is enabling sponsors and CRO partners with better management and execution of more highly complex clinical trials on a global scale.”
         

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters